These findings shed light on novel molecular mechanisms of glutamine metabolism modulation by SIRT4 and cross-talk between mitochondrial and nuclear sirtuins, suggesting that SIRT4 has tumor-suppressive activity and may serve as a novel therapeutic target in breast cancer. Here, SIRT4 is linked to breast carcinoma.